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HIDING BEHIND AGENCY DISCRETION: THE
FOOD AND DRUG ADMINISTRATION'S
PERSONAL USE DRUG
IMPORTATION POLICY
by Peter S. Reichertz and Melinda S. Friendt
INTRODUCTION
Seatbelts are mandatory, parents are forced to vaccinate their chil-
dren, and infectious people are quarantined: the law will curtail even the
most basic of human rights when the exercise of those rights poses a
threat to the public health.' Although less obvious, the Food and Drug
Administration (FDA or Agency) limits individual freedom in its mission
to protect public health.2 While most agree that some constraints on in-
dividual liberty are justified by FDA's role in serving the public at large,
the appropriate balance between the individual and public good is always
at issue. Nowhere is the conflict more sharply realized than in FDA's
general ban against the importation of unapproved drug therapies, espe-
cially when that ban functions to deny terminally ill people access to
unapproved, promising drug therapies.3
To ensure that drugs are safe and effective, the FDA generally pro-
hibits the importation of drug products if it has not granted pre-market
approval. 4 FDA's personal use exemption policy partially alleviates in-
dividual hardships caused by the general ban on the importation of unap-
t Peter S. Reichertz, is a partner at Arent, Fox, Kintner, Plotldn & Kahn, PLLC, practic-
ing in the areas of food and drug law and intellectual property. Mr. Reichertz received his J.D.
(with honors) from the George Washington University in 1975.
Melinda S. Friend is a GDRA Senior Manager with Novartis Consumer Health SA. Ms.
Friend received her J.D. (cum laude) from Georgetown University Law Canter and a M.P.H.
from Johns Hopkins School of Public Health in 1995.
1 Note that such public health laws are usually state laws, the authority for which is the
general state police powers. See Jacobson v. Massachusetts, 197 U.S. 11, 24-25 (1905)(up-
holding stated mandatory smallpox vaccination). In contrast, the federal government does not
possess any general police powers. See idL at 25.
2 In contrast to the general state police powers, the Federal Government's authority to
constrain individual rights to serve the public health generally rests on the "commerce clause"
of the Constitution, which grants the federal government the power "to regulate commerce...
among the several States.. ." U.S. CONST. art. I. §8, cl. 3.
3 The Federal Food, Drug, and Cosmetic Act requires a manufacturer to obtain FDA's
approval prior to delivering for introduction or introduction of the drug into interstate com-
merce. See Federal Food, Drug, and Cosmetic Act of 1938 §1, 21 U.S.C. §§ 301, 335(a)
(1998).
4 See id. § 381(a).
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proved therapies. The personal use exemption policy permits the
importation of small quantities of unapproved drugs for personal use on a
case-by-case basis.5 Neither codified by statute nor promulgated as a
regulation, the guidelines for personal use importation exist only in
FDA's Regulatory Procedures Manual.6 Consequently, the exemption is
almost exclusively implemented by individual FDA personnel from
whose decisions there is little meaningful appeal.
Individual FDA personnel do not have complete discretion to allow
importation of unapproved therapies for personal use, however; the
Agency routinely issues "import alerts" that absolutely prohibit entry of
certain drug products.7 Import alerts delineate certain drugs, or even
whole classes of drugs, that may not be admitted into the country even
where FDA personnel might otherwise permit entry under the personal
use exemption policy.8 The Agency's import alerts are issued as admin-
istrative decisions: again, there is little opportunity for public comment
or meaningful judicial review. 9
The odyssey of the AIDS buyers' clubs, 10 which the FDA permitted
to import large amounts of unapproved AIDS therapies under the per-
sonal use exemption policy, is the most obvious example of FDA's
defacto expansion of the policy in response to political pressure. Like-
wise, FDA's issuance of an import alert for the abortifacient drug RU-
486, that denied access to the drug in the United States for all purposes,
including cancer research, illustrates the willingness of FDA to contract
the scope of its policy in the face of political pressure."
The lack of legal procedures surrounding the formation and imple-
mentation of the personal use exemption policy, including import alerts,
leaves it uniquely vulnerable to abuse. The lack of procedural safeguards
5 In addition, a FDA regulation permits physicians to request permission to use an unap-
proved therapy on an emergency basis. See 21 C.F.R. § 312.36 (1998).
6 See FDA Regulatory Procedures Manual, Chapter 9, Subchapter on Coverage of Per-
sonal Importations (visited Feb. 20, 2000) <http://www.fda.gov/oralcompliance_ref/
rpmnew2/ch9pers.html> [hereinafter FDA Regulatory Procedures Manual].
7 See U.S. FOOD AND DRUG ADMINISTRATION AND DEPARTMENT OF HEALTH AND
HUMAN SERvicES, IMPORTS, (visited March 10, 2000) <http:llwww.fda.gov/oralimportl
oraimport_system.html> [hereinafter IMPORTs].
8 See id.
9 See id.
10 Acquired Immunodeficiency Syndrome (AIDS) is the name given to a particular set of
clinical markers and symptoms caused by infection with the human immunodeficiency virus
(HIV). The effects of HIV infection are not uniform, and people infected with HIV may be
perfectly healthy or quite sick even without a formal "AIDS" diagnosis. Although the term
"AIDS" is used throughout this paper, it should be understood to refer to the entire spectrum of
HIV infection.
11 See FOOD & DRUG ADMiN, Import Alert #66-47 (April 17, 1990) (visited march 10,
2000) <http:llwww.fda.gov/ora/fiars/ora-importia6647.html>. See also infra note 117 and
accompanying text.
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in the formation and implementation of the Agency's policy is particu-
larly troublesome because FDA's denial of access to an unapproved drug
may potentially deprive an individual of a lifesaving therapy. Indeed, the
importance of FDA's implementation of the policy to various groups has
at various times subjected the Agency to intense pressure both to expand
and contract the scope of its personal use exemption policy.
Unfortunately, the lack of Agency oversight and judicial review
means there is no guarantee that the FDA implements the personal use
exemption fairly, or that individual personnel allow importation for per-
sonal use in all deserving cases. Moreover, legal precedent established
by the RU-486 controversy and during the Laetrile Wars 12 - in which
FDA successfully prohibited terminally-ill cancer patients from taking
what they believed to be an effective and perhaps lifesaving unapproved
drug - make a legal challenge to the personal use exemption policy
virtually futile.
Given that the personal use importation exemption governs individ-
uals' access to potentially lifesaving drugs, the Agency has an ethical
duty to establish procedural safeguards to ensure the personal use exemp-
tion policy is developed and implemented consistently, fairly and effec-
tively. In recognition of the strength of judicial precedent, this Article
does not argue that the FDA has a statutory or constitutional mandate to
implement the personal use importation policy through notice-and-com-
ment rule making. Indeed, judicial precedent - rightly or wrongly -
establishes that there is no constitutional right to have access to a particu-
lar drug product. Instead, this Article argues from an ethical and policy
prospective, that the FDA should implement a regulation that ensures the
right of individuals to import unapproved drug products for personal use
in identified circumstances. Even if not legally mandated, there is no bar
to implementing the personal use exemption policy through notice-and-
comment rule making optimally as a binding, legislative rule.
Part I of this Article begins with an overview of FDA's general ban
on the importation of unapproved drug products and the policy reasons
for that ban. Part II provides ethical considerations that support the per-
sonal use exemption policy as well as practical justification for the pol-
icy. Part II provides FDA's current personal use exemption policy that
was widely utilized by the AIDS buyers' clubs. However, as discussed
in Part IV, an increase of the personal use exemption policy resulted in a
proliferation of off-shore companies who claimed their sale of unap-
proved drugs over the internet to domestic consumers is legal under the
personal use exemption policy. Part V provides an analysis of the legal
authority underpinning the personal use exemption policy, including im-
12 See infra notes 93-99 and accompanying text.
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port alerts, and the administrative and judicial review available to one
denied importation under the policy. Part VI of the article explores the
legal basis for implementing the personal use importation policy, includ-
ing import alerts, as a substantive interpretive rule through notice-and-
comment rule making procedures. Finally, Part VII concludes that trans-
forming the personal use importation exemption as a substantive rule will
have the effect of providing consistent guidelines while simultaneously
allowing potentially life-saving treatment for terminally ill patients.
I. FDA'S GENERAL BAN ON THE IMPORTATION OF
UNAPPROVED DRUGS
The FDA requires that imported, finished, prescription drugs be ap-
proved by the Agency under a New Drug Application (NDA) or Investi-
gational New Drug Exemption (IND). 13 During its lengthy and
exhaustive approval process, the FDA reviews evidence that a drug is
safe and effective for its intended use and that it is manufactured in ac-
cordance with the Agency's stringent current Good Manufacturing Prac-
tices.14 Compliance with Good Manufacturing Practices imposes
rigorous and detailed quality control procedures on the manufacture of
drug products. 15 FDA approval of a drug product extends only to the
manufacturer awarded approval. 16 The Agency therefore prohibits both
imports of drugs that have never been approved for use in the domestic
market and unapproved foreign-made versions of FDA-approved drugs.
There are several good reasons for prohibiting the import and use of
unapproved drugs. First, if the FDA has never approved a drug, the
Agency cannot ensure that the drug is either safe or effective for its in-
tended use. Second, the Agency cannot ensure that unapproved versions
of approved drugs are of high-quality: not only may unregulated drugs be
contaminated, adulterated, or mislabeled, their dose and potency may
also be substandard or inconsistent. Finally, the use of unapproved drugs
may interfere with the ability to conduct domestic clinical trials for drug
therapies seeking FDA approval. 17 This last factor is a particular prob-
lem in clinical trials for cancer and AIDS therapies.
13 See 21 U.S.C. §§ 355, 381(a)(3) (1998).
14 21 C.F.R. §§ 26.1-26.21, app.A-app.E (1999).
15 See id.
16 See 21 U.S.C. § 381(a) (1998).
17 The availability of unapproved drugs may decrease demand for participation in
clinical trials (i.e., research studies designed to determine the effect of an investigational drug
on human study subjects), particularly because in some clinical trials, participants run the risk
of receiving a placebo rather than the experimental treatment. See Rebecca Voelker, Several
New Drugs Shift Direction of Treatment and Research for HIV/AIDS, 275 JAMA 89-90
(1996). For clinical trials dealing with serious illness, participants may be unwilling to risk
receiving a placebo and prefer to seek unapproved therapies. In addition, the treatment effect
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II. THE NEED FOR A PERSONAL USE EXEMPTION
A. ETHICAL MANDATE TO PERMIT IMPORTATION FOR PERSONAL USE
While the law provides rules by which persons must abide or face
the coercive power of the state, ethics seeks to tell people what they
'ought' to do.18 When access to an unapproved drug therapy may be the
only chance for survival for an individual, yet will result in minimal neg-
ative effects on the public health, FDA 'ought' to ensure access to the
unapproved therapy.
To give a class of things moral status is to ascribe certain rights to
all members of that class. The moral rights of a class dictate the ethical
boundaries of its treatment, and may give rise to both negative and posi-
tive obligations. 19 If we posit a moral right to have access to medical
treatment based on a respect for individual life and autonomy, this right
creates a duty for society to provide protection for the exercise of that
right.20 Conversely, the traditional ethical limitation on state action is to
refrain from active harm of the individual without cause.21 That is, every
individual has a claim to justice and autonomy that limits the state's
power over that individual.22
When evaluating the ethics of a government agency action, the
question of whether and how an agency acts 'ethically' is often a ques-
tion of distributive justice - that is, identifying a just principle, by
which goods and burdens are distributed between individuals and
groups.2 3 Under most theories of distributive justice, to be ethical, gov-
ernment action must seek to balance burdens and benefits in order to
maximize goods for the greatest number of people. There must also be
of a drug being investigated in a clinical trial may be confused by study subjects' use of
unapproved therapies.
18 Loosely defined, the term 'ethics' refers to rules or values providing a measure by
which to evaluate our respective rights and responsibilities. There are numerous sources of
ethical guidelines, including religion, philosophy and tradition; obviously, there is not a single
accepted established system of ethics.
19 We would probably all agree, for example, that no living thing 'ought' to be intention-
ally tortured. This negative right ascribed to all living things may in turn give rise to a positive
obligation to stop someone from torturing another. See TOM L. BEAUCHAMP & JAMES F.
CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS 59-60 (3d ed. 1989).
20 As John Stuart Mill said, "I have treated the idea of a right as residing in the injured
person and violated by the injury ... To have a right ... is ... to have something which
society ought to defend me in the possession of." JOHN S. MILL, UTILITARIANISM 78-79
(1863).
21 See Dan E. Beauchamp, Community: The Neglected Tradition of Public Health, in
HASTINGS CENTER REPORT 28, 31-32 (Dec. 1985).
22 Some argue that the protection of the individual against coercive state regulation is the
essence of a just state. See AYN RAND, MAN'S RIGHTS, CAPITALISM: THE UN-
KNOWN IDEAL 320-29 (1967).
23 See BEAuCHAMP & CmiLDRnss, supra note 19, at 283.
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an appropriate procedure by which the substantive maximization of value
is applied correctly to each individual.
For example, a rule that would distribute limited food supplies dur-
ing famine to households in accordance with the number and ages of
each family member would generally maximize the public good. On the
other hand, if there were no procedure in place to determine and assure
appropriate distribution of the food, the actual distribution might be
made according to completely different principle - social status, for ex-
ample. Without both a substantive principle by which to distribute bene-
fits equitably and a procedure under which such distribution is assured,
government action cannot be considered to accord with established ethi-
cal norms.24 Moreover, although the government must seek to maximize
the public good, its actions are limited by the principles of individual
autonomy and beneficence accorded to all moral actors.
As discussed above, FDA's general prohibition on the import of
unapproved drug products serves to promote the public health in a vari-
ety of ways, including ensuring the safety and efficacy of drug products,
providing incentives for the participation in domestic clinical research
trials, and protecting the public from those who would profit from inef-
fective and even unsafe therapies and the desperation of the dying. On
the other hand, FDA's general prohibition can present a severe burden to
an individual when a promising drug product for a serious or life-threat-
ening condition is available only outside the United States. In such a
case, the benefit to the individual or group of individuals is potentially
great, while the threat to the public health is relatively small. In addition,
careful structuring of a regulation to permit personal use of unapproved
drugs under certain conditions could reduce any negative public health
consequences. Ethical theory behooves the Agency both to permit an
individual access to a promising, unapproved therapy under certain cir-
cumstances and to implement procedures by which individuals in appro-
priate situations could be identified and supported.
B. THE PRACTICAL NEED FOR A PERSONAL USE EXEMPTION
1. Travelers and Recent Immigrants
In practical terms, the FDA has long recognized that it has neither
the resources nor the mandate to regulate the importation of small
amounts of unapproved drugs for personal use by individuals.25 Con-
sider, for example, the number of travelers who begin a course of drug
24 See id. at 291.
25 The personal use importation was put in writing as early as 1954, in the form of a
directive to the Agency's district offices from FDA's Division of Field Operations. See RU
486: The Import Ban and its Effects on Medical Research: Hearing Before the Subcomm. on
Regulation, Business Opportunities, and Energy, 101st Cong., 2d Sess. 53, 175-77 (1990)(let-
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therapy for an acute condition while abroad and subsequently bring the
remaining course of the drug product back with them into the United
States. If the particular drug product has never been approved in the
United States or is a unapproved, foreign version of a drug product mar-
keted in the United States, importation of the drug is technically illegal. 26
In addition to travelers, Americans with recent ties to foreign countries
often seek pharmaceutical products that are unavailable domestically or
that have non-English labeling. 27
Obviously, the FDA must be aware of the importation of a drug
product in order to regulate such importation. The Agency requires that
all persons importing FDA-regulated products to file an entry notice with
the U.S. Customs Service.28 In addition, the Agency works closely with
Customs to identify mail and baggage shipments of drug products that
might violate FDA laws. Despite FDA's efforts, the amount of imported
products regulated by the FDA makes detection of such drugs products
very difficult.
2. Access to Unapproved Therapies to Treat Serious Illnesses
As the AIDS epidemic unfolded, the FDA came under intense pres-
sure to make potentially valuable unapproved drug products available to
critically ill people. In addition to criticizing FDA's drug approval pro-
cess, AIDS activists fought to gain access to promising new drugs avail-
able overseas. Other patient groups, particularly cancer groups, joined
with AIDS activists in their push for access to novel therapies for life-
threatening conditions only available from foreign sources.29
In 1982, the FDA published a proposed rule reforming the its regu-
latory process to expand and accelerate access to new drug products. 30
As part of its proposal, the FDA suggested that certain individuals would
be allowed to import a reasonable quantity of an unapproved drug prod-
uct for personal use into the United States.31 While permitting importa-
tion of small amounts of unapproved drug products for private individual
ter from FDA Acting Commissioner to Assistant Secretary of Health)[hereinafter RU-486
Hearing].
26 See 21 U.S.C. § 381 (1998).
27 Under the personal use exemption policy, the demand for unapproved foreign drug
products by individuals physically located in the United States is often met by importing drugs
through the mall. The FDA generally permits individuals to contact willing foreign physicians
who then mail the products directly to them. See FDA Regulatory Procedures Manual, supra
note 6.
28 See IMPoRTS, supra note 7.
29 See Elizabeth A. Silverberg, Note, Looking Beyond Judicial Deference to Agency Dis-
cretion: a Fundamental Right of Access to RU 486?, 59 BROOK. L. REV. 1551, 1571 (1994).
30 See New Drug and Antibiotic Regulations, 47 Fed. Reg. 46,622, 46,642 (1982) (pro-
posed Oct. 19, 1982).
31 See id.
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use purposes, the Agency noted that it would continue to prosecute those
seeking to import unapproved products for financial gain. 32 The FDA,
however, did not include the proposed importation exemption in its final
regulations on expediting drug approvals, stating that it found its "policy
related to enforcement discretion is better stated in a compliance policy
guide."33
In 1987, the New York-based PWA Health Group formed the first
"buyers' club" for the purpose of importing unapproved AIDS drugs into
the United States.34 Initially, the group contracted with a domestic com-
pany to manufacture AL721. AL721 is a drug that was then available in
Israel, and is made from Jipids derived from eggs.3 5 The PWA Health
Group characterized AL721 as a food additive and notified both FDA
and the media that they would begin to distribute AL721, expecting to
publicize the anticipated confrontation with the Agency.3 6 Instead, the
FDA chose to ignore the Club's distribution of AL721.37
One year later in July 1988, the Agency issued a "Pilot Guidance"
announcing that, under certain conditions, people with AIDS or cancer
would be allowed to import by mail small quantities of unapproved drug
products for their personal use under physician supervision.38 FDA
Commissioner Young then announced FDA's personal use exemption
"Pilot Guidance" at the National Lesbian and Gay Health Conference
and AIDS Forum in Boston. 39 A concurrent FDA Talk-Paper explicitly
noted that people with AIDS had been importing small quantities of dex-
tran sulfate, an unapproved drug product which had long been sold over-
the-counter in Japan for use in lowering cholesterol. 40
The PWA Health Group also began importing and distributing dex-
tran sulfate, its second product, in 1988. FDA's Pilot Guidance along
32 See id.
33 New Drug and Antibiotic Regulations, 50 Fed. Reg. 7452, 7488 (1985)(to be codified
at 21 C.F.R. pt. 314.410(a)).
34 See Paula Span, Pharmacy for the Desperate, WASH. POST, Apr. 8, 1992, at Dl.
35 See id. at D2.
36 See Eric Lindemann, Note, Importing AIDS Drugs: Food and Drug Admhistration
Policy and its Limitations, 28 G.W.J. INT'L L. & ECON. 133, 154 (1994); See also Span,
supra note 34.
37 See Span, supra note 34, at D2.
38 See FDA Will Allow Mail Import of Unapproved Drugs, THE GREEN SHEET (FDA/
Weekly Pharmacy Reports), Aug. 1, 1988, at 2-3, available in LEXIS, Market and Industry
Library, Medical and Healthcare Folder, Green Sheet-Pharmacy File; RU-486 Hearing, supra
note 25, at 162 (memorandum from FDA/Director, Office of Regional Operations, regarding
"Pilot Guidance for Release of Mail Importations").
39 See FDA Will Allow Mail Import of Unapproved Drugs, supra note 38; FDA Allowing
Individuals to Import by Mail Unapproved Drugs in Personal, THE GREEN SHEET (FDA/
Weekly Pharmacy Reports), Aug. 8, 1988, at 4, available in LEXIS, Market and Industry
Library, Medical and Healthcare Folder, Green Sheet-Pharmacy File.
40 See FDA Will Allow Mail Import of Unapproved Drugs, supra note 38, at 3.
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with its tolerance of the PWA Health Group's activities resulted in the
rapid formation of other buyers' clubs for the importation of AIDS drugs.
The buyers' clubs explicitly justified the legality of their activities on
FDA's personal use exemption policy.4 1
I. THE RESULTING PERSONAL USE EXEMPTION POLICY
A. FDA's PERSONAL USE EXEMPTION POLICY
On February 1, 1989, the "Pilot Guidance" on personal use importa-
tion was formalized as a revision to Chapter 9-71 of FDA's Regulatory
Procedures Manual.42 As noted in a current U.S. Customs Traveler's
Alert, FDA's personal use importation policy simply "represents FDA's
current thinking regarding the issues of personal importation and is in-
tended only to provide operating guidance for FDA personnel. The gui-
dance does not create any legally enforceable rights for the public; nor
does it operate to bind FDA or the public."43
The Guidance is still in effect and permits importation of unap-
proved drug products for personal individual use under the following
conditions, not specifically reserved for people with AIDS or cancer:
SCENARIO -- Treatment of non-serious condition
a) The intended use is appropriately identified; and
b) The use is not for the treatment of a serious condition; and
c) The product is not known to represent a significant health risk.
SCENARIO 2 - Treatment of a serious or life-threatening condition
a) The intended use is unapproved; and
b) The drug will be used to treat a serious condition for which ef-
fective treatment may not be available domestically either
through commercial or clinical means; and
c) There is no known commercialization or promotion to persons
residing in the United States by those involved in the distribution
of the product at issue; and
d) The product is considered not to represent an unreasonable risk;
and
e) The individual seeking to import the product affirms in writing
that is for the patient's own use (generally not more than a 3
month supply); and
41 See PWA Health Group, Welcome to the People with AIDS Health Group (last modi-
fied Oct. 8, 1997) <http:lwww.aidsinfonyc.orglpwahglwelcome.htm>.
42 See FDA Regulatory Procedures Manual, supra note 6.
43 FOOD & DRUG ADMIN, FDA/ORA IMPORT OPERATION TRAVELER'S ALERT, IMPORTA-
TION OF PRSCRITnON MEDICINES/DRUGS 2 (1997) (visited Feb. 20, 2000) <http://
www.fda.gov/ora/import/traveler-alert.htm>.
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f) The individual provides the name and address of the doctor li-
censed in the United States responsible for his or her treatment
with the product or provides evidence that the product is for the
continuation of a treatment begun in a foreign country."4
The personal use exemption policy itself has several provisions
whereby the FDA can exert control over the safety of drug products im-
ported under the exemption. First, drugs subject to a FDA import alert
are banned from import under the personal use exemption policy.45 The
FDA will issue an import alert if it has safety concerns regarding a par-
ticular drug product or manufacturer. 46 When it announced its policy,
FDA had 40 import alerts in effect covering particular drug products,
manufacturers and distributors.47 Second, FDA's policy advises agency
personnel to permit only importation of drugs that do not represent an
unreasonable health risk.48 Finally, the Agency requires that the person
importing the drug either provide the name and address of the physician
under whose supervision the drug will be taken, or provide evidence that
the product is for the continuation of a treatment begun in a foreign
country.49
B. AIDS BUYERS' CLUBS EXPAND THE PERSONAL USE EXEMPTION
The buyers' clubs almost immediately pushed to expand the bound-
aries of FDA's personal use importation policy after the policy was an-
nounced. First, the buyers' clubs imported large quantities of AIDS
drugs, far exceeding a three-month supply for any one individual.50 Sec-
ond, arguing that access to drugs meant being able to afford them, many
clubs began to import less expensive foreign versions of drugs approved
in the United States.5 ' The PWA Health Group, for example, had im-
ported fluconazole (a drug to treat fungal infections) for a year prior to
44 See FDA Regulatory Procedures Manual, supra note 6.
45 An import alert is issued in the form of an internal FDA memorandum to Agency field
agents in district offices and advises the field agents that a particular drug or manufacturer's
products should not be admitted under the personal use exemption policy and why. See IM.
PORTS supra note 7.
46 See id.
47 See FDA, Policy on Importing Unapproved AIDS Drugs for Personal Use (copy on
file with author).
48 See FDA Regulatory Procedures Manual, supra note 6.
49 See id.
so See Span, supra note 34, at Dl (noting that in 1991 it is estimated that 5,000 people
bought $1.25 million of products from AIDS Buyers' Clubs).
51 See Aerosol Pentamidine Will Be Imported by AIDS Underground Buyers Group at
Sharply Lower Prices, THE BLUE SHEET (FDA/Drug Research Reports), Sept. 27, 1989, at 2-
3, available in LEXIS, Market and Industry Library, Medical and Healthcare Folder, Blue
Sheet-Health Policy and Research File.
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its approval by FDA.52 The club then announced that it would not decide
whether to stop importing the unapproved version of fluconazole until its
U.S. manufacturer, Pfizer, announced the drug's price.53 In addition, nu-
merous buyers' clubs offered pentamidine (to treat a common AIDS-re-
lated pneumonia) far below the U.S. drug's cost.54 Because the personal
exemption policy explicitly requires that the imported drug product be
unapproved for its intended use in the United States, once the FDA ap-
proves the drug in the United States, the buyer's clubs are no longer able
to rely on the personal use exemption. Consequently, the buyers' clubs
are compelled to pay the higher prices, or else risk prosecution by the
FDA.
C. THE FDA's RESPONSE TO SAFETY CONCERNS UNDER THE
EXPANDED POLICY
The FDA was sensitive to safety issues surrounding the reimporta-
tion into the United States of drugs that were originally manufactured in
the United States and distributed to a foreign market. Because drug
products manufactured in the United States are often sold at lower prices
in foreign markets, companies were diverting drugs from the foreign
market, reimporting them to the United States and selling them at a dis-
count.55 The Agency, however, could not regulate the handling or safety
of drug products during the time of their export, in other words, there
was no guarantee that reimported packages even still contained the drug
product as labeled. Because of safety concerns, § 801(d)(1), a part of the
Prescription Drug Marketing Act of 1987, banned the reimportation of
exported products except when reimportation was by the original manu-
facturer of the drug.56
In-so-far as high U.S. drug prices reflected superior quality and
safety, the FDA had every incentive to close off the personal use exemp-
tion because of its use as a tool to circumvent the higher costs of domes-
tic drugs. For example, in 1990, Virginia Medicaid sought to import an
unapproved foreign version of Sandoz's Clozaril, an antischizophrenic
52 See Pfizer Diflucan Approved Jan. 29 for AIDS-related Fungal Infections, 1AA Rated
Drug Earns FDA Okay in Less Than Year. Shipment to Begin Feb. 16, THE PINK SHEET
(FDA/F-D-C Reports), Feb. 5, 1990, at 5-6, available in LEXIS, Market and Industry Library,
Medical and Healthcare Folder, Pink Sheet-Pharmaceuticals, Prescriptions and OTC Medica-
tions File.
53 See id.
54 See Deithia Ricks, AIDS Drug Clubs Offer Hope from Overseas, Buyers' Clubs Are
Walking a Thin Legal Line When They Import Unapproved Medication for Desperate Patients,
ORLANDO SENTINEL TRIB., July 12, 1992, at Al.
55 See 133 CONG. REc. H3021 (daily ed. May 4, 1987) (statement of Rep. Alexander).
56 See Prescription Drug Marketing Act of 1987, § 801(d)(1), 21 U.S.C. § 381(d)(1)
(1998).
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drug, because the foreign product was less expensive.5 7 The cost of San-
doz's product, however, in part reflected the extensive post-marketing
monitoring system that the Agency required Sandoz to maintain as part
of its marketing approval. Although the Commonwealth of Virginia pro-
posed to conduct its own monitoring, FDA denied Virginia's request to
act as a buyers' club for Clozaril.5 8
The debate over reimportation has recently begun anew. Charging
that Americans pay much more for prescription pharmaceuticals than
people in other nations, particularly Canada, many have challenged Con-
gress to permit reimportation of approved drugs by wholesalers, distribu-
tors and pharmacists. Legislation to allow reimportation has been
introduced in both the House and Senate, and the American Medical As-
sociation has resolved to support such legislation.59 Even Hillary Clinton
has gone on record saying that reimportation, at least from Canada, is a
good idea as long as safety can be assured.60
The FDA, however, has continued to permit the buyers' clubs to
operate freely. The activist community vociferously charged that FDA's
refusal to allow access to therapies was tantamount to murder; unable to
withstand the onslaught, the Agency permitted the buyers' clubs to im-
port unapproved drug products with little interference. In enforcing the
personal use exemption policy, the Agency generally tried to draw a
clear line between commercial importation of unapproved drugs and im-
portation of potentially lifesaving drugs for nonprofit, humanitarian rea-
sons.6 ' The buyers' clubs continued to serve as sources for unapproved
therapies until the very safety and quality issues the Agency cites to jus-
tify its general ban on unapproved drug products materialized.
In the early 1990's, Hoffman-LaRoche began clinical trials with
dideoxycytidine (ddC), a step in seeking FDA-approval of the drug. At
the time, ddC was one of the most popular drugs imported by the buyers'
clubs.62 In what was to be an extremely effective play for market domi-
nance, Hoffman-LaRoche analyzed several samples of ddC from buyers'
57 See Virginia Medicaid Clozaril Importation Proposal troubles FDA, Could be Elicit
(sic), THE GREEN SHEET (FDA/Weekly Pharmacy Reports), Nov. 26, 1990, at 2, available
in LEXIS, Market and Industry Library, Medical and Healthcare Folder, Green Sheet-Phar-
macy File
58 See id.
59 See AMA Delegates Adopt Resolution To Support Allowing Rx Drug Reimportation,
HEALTH NEWS DAILY (FDA/F-D-C Reports), Dec. 9, 1999, at 1, available in LEXIS,
Market and Industry Library, Medical and Healthcare Folder, FDC Health News Daily File.
60 See Adam Nagourney, Mrs. Clinton Favors American Access to Cheaper Canadian
Medicines, THE NEW YORK Tnms, Feb. 9, 2000, at B5. Representative Bernie Sanders main-
tains a collection of press articles surrounding the reimportation effort on the Internet at, (vis-
ited March 9, 2000) <http://bemie.house.gov/legislation/pharmbillpress.asp>.
61 See, e.g., FDA News Release P92-3, Jan. 30, 1992 (visited Feb. 20, 2000) <http:ll
www.fda.govlbbs/topics/NEWS/NEWOO265.html>.
62 See Span, supra note 34, at D2.
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clubs and found them to be substandard. The FDA subsequently investi-
gated and found that some of the drug sold through the buyers' clubs as
ddC did not contain dideoxycytidine at all, and almost none of the other
imported ddC met accepted potency or purity standards. 63 All but one
buyers' club stopped providing imported ddC due to the incontestable,
documented quality problems with the unapproved products.64 As a re-
sult of the ddC quality problems, many in the AIDS community began to
reassess the appropriate balance between access to unapproved drugs and
government regulation that could ensure quality.65
In 1991, the FDA announced a new program to inspect buyers'
clubs. In general, the Agency was looking for evidence that the clubs
were used for commercial purposes, or that they were engaged in the
repackaging and recompounding of drugs, activities which FDA strictly
regulates.66 The Agency clarified in a Talk Paper that the personal use
importation policy did not allow the import of drugs approved for use in
the United States, and in 1993, the Agency began a program to identify
promising AIDS drugs that have not been approved in the United
States.67
IV. RAMIFICATIONS UNDER THE PERSONAL USE
EXEMPTION POLICY
A. THE DECLINE OF THE AIDS BUYERS' CLUBS
In the mid- and late-90's, several developments helped to expand
access to drugs for AIDS-related conditions, thus lessening the need for
buyers' clubs to act as clearinghouses for inaccessible therapies. First,
AIDS activists were successful in forcing the FDA and pharmaceutical
companies to expand access to therapies under development in the
63 See Parallel Track Regs Will Be Expanded to Include Drugs For Serious Illnesses
Other Than AIDS Once FDA Is Assured Ongoing Trials Are Not Affected-Kessler, THE
PINK SHEET (FDA/F-D-C Reports), Apr. 13, 1992, at 12-13, available in LEXIS, Market
and Industry Library, Medical and Healthcare Folder, Pink Sheet-Pharmaceuticals, Prescrip-
tions and OTC Medications File; T & G In Brief, THE PINK SHEET (FDA/F-D-C Reports),
Mar. 9, 1992, at T&G-13, 21, available in LEXIS, Market and Industry Library, Medical and
Healthcare Folder, Pink Sheet-Pharmaceuticals, Prescriptions and OTC Medications File.
64 See Span, supra note 34, at D2.
65 See id.
66 See FDA to Inspect Buyers' Clubs For Unapproved AIDS Drugs to Guard Against
Profiteering, Ensure Safety, THE BLUE SHEET (FDA/Drug Research Reports), Oct. 2, 1991,
at 10, available in LEXIS, Market and Industry Library, Medical and Healthcare Folder, Blue
Sheet- Health Policy and Research File
67 See Health Care Fraud Penalties to Be Proposed by Rep. Schumer: AIDS Buyers
Clubs Cautioned, THE BLUE SHEET (FDA/Drug Research Reports), June 2, 1993, at 11-12,
available in LEXIS, Market and Industry Library, Medical and Healthcare Folder, Blue Sheet-
Health Policy and Research File.
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United States but not yet approved. 68 Second, the FDA greatly reduced
approval times for drugs, especially AIDS therapies, through its acceler-
ated approval program. 69 Third, programs such as the AIDS Drug
Assistance Program ("ADAP") helped to ensure economic access to
AIDS-related therapies.70 Finally, the advent in the United States of the
most successful drug treatment to date - protease inhibitors - served
to focus demand for AIDS therapies on approved drug products.
Today, many AIDS buyers' clubs are still alive and well, with sev-
enteen organizations listed on one directory available on the Internet.7t
Most of the buyers' clubs, however, have discontinued importing unap-
proved drug products; instead, they generally offer information about and
access to pharmaceutical-grade (when available) dietary supplements,
which are legally available without a prescription and do not require
FDA pre-market approval. 72 Although at least the PWA Health Group
still provides access to some unapproved drug therapies from abroad, the
drug-importing function of the buyers' clubs is no longer as important
because most therapies are both financially and physically accessible in
the United States, at least for motivated people.73
68 See Lois K. Perrin, Note, The Catch-22 For Persons With AIDS: To Have or Not to
Have Easy Access to Experimental Therapies and Early Approval for New Drugs, 69 S. CAL.
L. REV. 105 (Nov. 1995). For example, FDA's treatment INDs give people without satisfac-
tory alternatives access to investigational (unapproved) new drugs. The expanded access pro-
gran allows people without other treatment alternatives to receive investigational drugs in
conjunction with research studies, even through the person is ineligible for the particular study.
See Active Treatment IND/Expanded Access Programs, PHARMACEUTICAL APPROVALS
MONTHLY (FDA/F-D-C Reports) Jan. 1, 1998, at 19 (copy on file with author).
69 See Dng Approvals Do Not Lag in U.S. Compared to Rest Of World, Com. Kessler
Tells FDLI: International Side-by-Side Approval Comparison Shows U.S. Ahead, THE PINK
SHEET (FDA/F-D-C Reports), Dec. 18, 1995, at 9-10, available in LEXIS, Market and Indus-
try Library, Medical and Healthcare Folder, Pink Sheet-Pharmaceuticals, Prescriptions and
OTC Medications File. In addition, recent legislation enacted several reforms to expedite ap-
proval of important drugs and to expand the information resources about ongoing research
with experimental drugs. See Food and Drug Administration Modernization Act of 1997,
§ 506, 21 U.S.C. § 356 (1998).
70 ADAP is a state-run program that uses a mix of federal and state funds to provide
drugs used to treat HIV and related opportunistic infections to low-income people. Other
publicly-funded HIV services include the Ryan White CARE Act of 1996, 42 U.S.C. §§ 201,
300ff-l1 (1998), Medicaid, Medicare, and local indigent health care programs. In 1997 total
ADAP spending was $385 million, but despite spending increases, most ADAP programs im-
posed limits on their services in 1997 because of the growing cost of, and demand for, AIDS-
related drugs, especially protease inhibitors. See Press Release, The Kaiser Family Foundation
(Jul. 10, 1997) (visited Feb. 20, 2000) <http:llwww.kff.orglcontentlarchive/1275/adapr.html>.
71 See ACT UP: Real Treatments for Real People (last modified June 4, 1999) <http:ll
www.aidsinfonyc.org/rtrp/buyers.html>.
72 Personal Communication with Mark Neidzolkowsk, Editor, The PWA Health Group
Newsletter (Feb. 2, 1999).
73 The welcome message on PWA Health Group's web site provides a glimpse of the
struggle between AIDS activists and FDA:
We openly operate the Early Treatment Access Program under the FDA's Personal
Use Importation Guidance, which permits people to bring in a three month's supply
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B. RECENT ISSUES UNDER THE PERSONAL USE EXEMPTION POLICY
Many companies explicitly justify their solicitation of United States
consumers to order unapproved products by mail under FDA's personal
use importation policy. In 1992, the FDA issued an import alert list of
prescription drugs from six foreign mail-order drug firms. The Agency
claimed both that the companies were promoting the drugs for unap-
proved uses and that the drugs were of substandard quality and in some
cases counterfeit.74 In 1995, a company called Medicine Club Interna-
tional was charged with shipping an unapproved version of Prozac®
(fluoxetine) to the United States.75 Medicine Club, like other companies,
advertised unapproved versions of United States pharmaceuticals at dis-
count prices. Medicine Club's advertisements contained an 800 number
and offers to sell the drug in personal use quantities.76 Medicine Club
International was fined $500,000, in addition to making a $339,074 pay-
ment for the costs of the investigation. 77 The company, along with sev-
eral other companies conducting similar mail-order businesses that were
not prosecuted, agreed to establish a $1 million letter of credit that would
be forfeited to the United States if the companies offer unapproved,
adulterated or misbranded drugs for sale before the year 2000.78
The FDA has also expressed concern with the proliferation of on-
line, offshore pharmacies, which have continued to attempt to profit from
the personal use exemption policy. For example, in a speech to the
American Pharmaceutical Association's annual meeting in March of
1997, a FDA Senior Science Advisor noted that several offshore compa-
nies were offering generic versions of drugs with potentially serious side-
of a medication approved elsewhere in the world. It sounds simple, and aside from
periodic FDA harassment, it usually is. But it's also important to remember that
each time you buy something here at the PWA Health Group, you're performing a
political act. Throughout the history of the AIDS crisis in the United States, people
with HIV/AIDS have refused to accept the limited wisdom of our government, the
medical profession, and the drug companies. We question, we argue, we confront,
and, though all of this, we make individual empowered treatment decisions that are
right for us. We are proud of this history of struggle and caring, which has been
critical to the treatment advances of today, and critical to the place we urgently need
to get to a cure.
See PWA Health Group, supra note 41. The PWA Health Group continues to import certain
therapies that drug companies are unwilling to sponsor for FDA approval for economic
reasons.
74 See FDA News Release P92-3, Jan. 30, 1992 (visited Feb. 20, 2000) <http:fl
www.fda.gov/bbs/topics/NEWS/NEW00265.html>.
75 See Medicine Club pleads guilty to shipping unapproved generic Prozac, THE PINK
SHEET (FDA/F-D-C Reports), Jan. 9, 1995, at T&G-2, available in LEXIS, Market and In-
dustry Library, Medical and Healthcare Folder, Pink Sheet-Pharmaceuticals, Prescriptions and
OTC Medications File.
76 See id.
77 See id.
78 See id.
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effects due to bioequivalency issues.79 In general, these companies offer
the drugs for personal use and advise physician supervision. Although
the companies may explicitly claim to operate within FDA's personal use
exemption, they violate the personal import exemption on several fronts.
First, the companies import drug products for commercial gain. Second,
most of their products are approved for use in the United States and thus
not eligible for the personal use import exemption if they treat a serious
condition. Third, the drug products are often adulterated or misbranded.
Because these companies are off-shore, it is often very difficult for the
FDA to identify the companies and curtail their activities. The Agency
has been working to establish cooperative efforts with the countries from
which these exporters operate.80
In December 1999, The White House announced a new initiative to
curtail the illegal sale of prescription drugs over the Internet.81 Citing
the danger to consumers posed by unregulated and illegal Internet phar-
macies, and the increasing proliferation of such operations, President
Clinton proposed a multi-prongs response, including a $10 million ap-
propriations in the FY 2001 budget to expand federal enforcement activi-
ties against "Fly by Night" Internet pharmacies. 82 The program has
several parts, including bringing Internet pharmacies into compliance
with existing pharmacy regulations; strengthening the investigative tools
and monetary penalties against illegal Internet pharmacies; and creating a
new online program to raise public awareness about illegal Internet drug
sales. FDA's Internet site to assist consumers in filling prescriptions
safely over the Internet is now up and running.83
V. LEGAL CHALLENGES TO FDA'S PERSONAL USE
IMPORTATION POLICY
Because FDA's personal use importation policy is implemented
through the exercise of FDA's enforcement discretion, the Agency has
little public or judicial accountability for its decisions to permit or pro-
hibit importation of a drug under the policy. Imagine that you are seri-
79 See Internet Generic Phenytoin Sales Are Public Health Concern, THE GREEN
SHEET (FDA/Weekly Pharmacy Reports), Apr. 6, 1998, at 3, available in LEXIS, Market and
Industry Library, Medical and Healthcare Folder, Green Sheet-Pharmacy File.
80 See In Home Generic Phenytoin Off-shore Sales of Concern to FDA Because Use of
Non-approved Generic May Change Blood Levels of the NTI Drug, Bersein Tells APhA Meet-
ing, HEALTH NEWS DAILY (FDA/F-D-C Reports), Mar. 26, 1998, at 3, available in LEXIS,
Market and Industry Library, Medical and Healthcare Folder, FDC Health News Daily File.
81 See Office of the Press Secretary, The Clinton Administration Unveils New Initiative
To Protect Consumers Buying Prescription Drug Products Over the Internet (Dec. 28, 1999)
(visited March 6, 2000) <http://www.fda.gov/oc/buyonline/onlinesalespr.html>.
82 See id.
83 See FDA, Buying Medical Products Online (visited March 4, 2000) <http://
www.fda.gov/oc/buyonline>.
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ously ill with a rare disease. In consultation with your doctor, who
advises you that a drug available only in Germany provides the best
treatment, you fly to Germany to obtain a three-month supply. On your
return through customs in New York, an agent confiscates the drug, re-
fusing to exercise his enforcement discretion to permit the importation of
an unapproved drug product in contravention to the Federal Food, Drug
and Cosmetic Act ("FDCA"). 84 Alternatively, the FDA has issued an
import alert banning all drug products made by the German manufacturer
in question, taking away the agent's enforcement discretion to permit
import of the drug for personal use.
You could challenge the agent's denial or the Agency's issuance of
an import alert on several fronts, all of which would likely fail. First,
you could appeal the denial through FDA's own administrative proce-
dures. 85 Second, you could bring a legal action against the Agency
claiming one or more of the following: (1) the Agency's denial exceeded
its statutory or constitutional authority; (2) the Agency's denial was arbi-
trary and capricious and should thus be overturned under the Administra-
tive Procedure Act (APA); 86 and (3) the Agency's personal use
exemption policy or import alerts are substantive rules that must be
promulgated by notice-and-comment rule making under the APA and are
therefore void.87 As discussed below, administrative law and judicial
precedent would virtually ensure the failure of both your administrative
appeal to the FDA and of an appeal to the courts.
A. ADMINISTRATrVE APPEAL TO FDA
Having been denied importation of the German drug for personal
use, you could contest the refusal at an administrative hearing. By regu-
lation, the Agency must issue a written notice providing the reason for
the refusal and the time and place of a hearing at which there is an oppor-
tunity to defend the legality of importing the drug.88 If the FDA was
unsympathetic to your case, however, the fact that you met all the criteria
of the personal use exemption policy would be moot. If the drug is unap-
proved, there is no right to import it, regardless of your compliance with
the terms of the personal use importation policy. 89 Because the FDA
84 See Federal Food, Drug, and Cosmetic Act of 1938 §1, 21 U.S.C. §§ 301-397 (1998).
85 See id. § 334 (1998).
86 See 5 U.S.C. § 706(2)(A) (1998).
87 See id. § 553(b), (c).
88 See 21 C.F.R. § 1.94 (1999).
89 A court would probably even permit FDA to forgo the hearing unless the importer
could show there was a genuine issue regarding the approval status of the drug product. See
Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609 (1973)(permitting the FDA to
deny a statutorily mandated hearing regarding a drug's efficacy unless the manufacturer could
show there was a genuine and substantial issue of fact to be presented at the hearing).
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itself claims absolute discretion to deny the importation of any unap-
proved drug, there is no meaningful appeal to the Agency regarding such
a denial.
B. FDA's CONSTITUTIONAL AUTHORITY TO DENY IMPORTATION FOR
PERSONAL USE
Failing an administrative appeal, you could challenge FDA's impor-
tation denial in the courts, claiming that it violates individual rights pro-
tected under the United States Constitution. Intuitively, government
action denying an individual access to a potentially lifesaving treatment
would seem to violate the constitutional protection of privacy rights and
individual autonomy, especially as those rights have been interpreted by
the Supreme Court.90 Certainly, the person with a terminal illness from
whom the FDA confiscates an unapproved drug intended only for per-
sonal use must feel that confiscation to be a grave violation of his auton-
omy and privacy.91 However, due to well-established judicial precedent
described below, an appeal to the courts to overturn FDA's denial of
importation for personal use on constitutional grounds has little hope of
prevailing.
In litigation spanning twelve years, terminally ill cancer patients
seeking to obtain the use of the drug Laetrile, 92 that many then believed
to be an effective cancer treatment, sought to challenge FDA's right to
prohibit their use of Laetrile as an unapproved new drug.93 Generally,
the cancer patients argued that because they were dying anyway, they
had little to lose if Laetrile did not work and should therefore be permit-
ted access to the drug. The FDA categorically responded that it was
impossible to know whether a cancer was actually terminal and permit-
ting the use of an unproven therapy could prevent people with cancer
90 See, e.g., Whalen v. Roe, 429 U.S. 589 (1977); Planned Parenthood of Central Mis-
souri v. Danforth, 428 U.S. 52 (1976); Doe v. Bolton, 410 U.S. 179 (1973); Paris Adult Thea-
tre I v. Slaton, 413 U.S. 49 (1973); Roe v. Wade, 410 U.S. 113 (1973); Eisenstadt v. Baird,
405 U.S. 437 (1972).
91 If an Agency decision (not to permit importation of unapproved drugs for personal
use) violates the Constitution, it will be reversed under § 706(2)(B) of the APA. See 5 U.S.C.
§ 706(2)(B) (1998). Moreover, an agency cannot interpret a statute in such a way that the
interpretation raises a serious constitutional issue absent a "clear statement" from Congress
supporting the interpretation. See DeBartolo Corp. v. Florida Gulf Coast, 485 U.S. 568
(1988).
92 Laetrile is a compound usually derived from apricot pits that many cancer patients
believe to be an effective treatment.
93 See Rutherford v. United States, 806 F. 2d 1455 (10th Cir. 1986); Rutherford v.
United States, 616 F.2d 455 (10th Cir. 1980); Rutherford v. United States, 582 F.2d 1234 (10th
Cir. 1978); Rutherford v. United States, 542 F.2d 1137 (10th Cir. 1976); Rutherford v. United
States, 438 F. Supp. 1287 (W.D. Okla. 1977); Rutherford v. United States, 429 F. Supp. 506
(W.D. Okla. 1977); Rutherford v. United States, 424 F. Supp. 105 (W.D. Okla. 1977); Ruther-
ford v. United States, 399 F. Supp. 1208 (W.D. Okla. 1975).
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from seeking treatment with effective, approved therapies. In addition,
the FDA cited the dangers of unethical practitioners who provided false
hope to the terminally ill for their own financial gain.94
In 1977, at the beginning of the Laetrile wars, the United States
District Court for the Western District of Oklahoma passionately de-
fended the right of terminally-patients to use Laetrile under the Constitu-
tion. The court in Rutherford v. United States argued:
The final consequences [of FDA's denial] are ultimately borne by
those whose bodies are the battleground on which cancer's war is waged.
Many perceive the drug's acquisition as a life and death matter, and are
understandably frustrated and enraged over attempts by their own gov-
ernment to deny them the right to decide for themselves questions of
such a personal and grave nature.... To be insensitive to the very funda-
mental nature of the civil liberties at issue in this case, and the fact that
making the choice, regardless of its correctness, is the sole prerogative of
the person whose body is being ravaged, is to display slight understand-
ing of the essence of our free society and its constitutional underpin-
nings.... By denying the right to use a nontoxic substance in connection
with one's own personal healthcare, FDA has offended the constitutional
right of privacy. 95
On appeal, however, the 10th Circuit Court of Appeals held that
although the choice of whether to have medical treatment or not is a
privacy right protected by the Constitution, this protection does not ex-
tend to the selection of a particular treatment. 96 Instead, the court found
that "the selection of a particular treatment, or at least a medication, is
within the area of governmental interest in protecting public health. '97
The litigation over access to Laetrile thus established FDA's constitu-
tional authority to deny access to unapproved drug products for personal
use even in the case of patients with terminal cancer.98
94 See, e.g., United States v. Rutherford, 442 U.S. 544 (1979).
95 438 F. Supp. 1287, 1300-01, (W.D. Okla. 1977).
96 See Rutherford v. United States, 616 F.2d 455, 457 (10th Cir. 1980), cert denied, 449
U.S. 937 (1980). See also Carnohan v. United States, 616 F.2d 1120, 1122 (9th Cir. 1980);
Sifre v. Robles, 917 F. Supp. 133, 137 (D.P.R. 1996); Jacob v. Curt, 721 F. Supp. 1536, 1539
(D.R.I. 1989); Kulsar v. Ambach, 598 F. Supp. 1124 (W.D.N.Y. 1984); Gadler v. United
States, 425 F. Supp. 244 (D. Minn. 1977).
97 See Rutherford, 616 F.2d at 457.
98 Laetrile is still subject to FDA Import Alert no. 62-01, (visited March 10, 2000)
<http:llwww.fda.gov/oralfiars/ora-importia6201.html>, and the Agency has threatened en-
forcement actions against companies attempting to market Laetrile as a dietary supplement.
See FDA warns Florida company it is making 'drug' claims for dietary supplements, LAE-
TRILE FOOD LABELING & NUTRITION NEWS, Dec. 23, 1998, at 10 (copy on file with
author).
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C. FDA's STATUTORY AUTHORTY TO PROHIBIT IMPORTATION FOR
PERSONAL USE
Having been denied your appeal on Constitutional grounds, you
would be left to argue that the FDA exceeded its statutory authority in
prohibiting importation of the unapproved drug for personal use. Under
the APA, the initial question for the court would be whether the FDA has
the statutory authority to prohibit the importation of unapproved drugs
for personal use.99 In reviewing FDA's claim of statutory authority, the
Court would first inquire whether "Congress has directly spoken to the
precise issue at hand."'1
The FDA cites § 801 of the FDCA as requiring the Agency to pro-
hibit the importation of unapproved, new drug products. Section 801
itself, however, simply prohibits the importation of unapproved drugs
that will be introduced into interstate commerce.10 1 If personal importa-
tion and use of a drug does not constitute an "introduction into interstate
commerce," then such importation and use are not a violation of
§ 801.102 Outside a courtroom, few would argue that a person who ob-
tains and personally uses an unapproved drug from a foreign source
thereby 'introduces' that drug into interstate commerce, even though it
satisfies the statutory definition.10 3
The FDA however, interprets § 801 to mandate a general ban on the
importation of unapproved, new drug products, even when those prod-
ucts are intended for personal use.1°4 In addition, there is judicial prece-
dent that the FDCA's prohibition on the introduction into interstate
commerce of unapproved drugs does extend to unapproved drugs im-
ported for personal use. In Galder v. United States,0 5 the court denied
an injunction to a cancer patient seeking to restrain the FDA from
prohibiting import of Laetrile for his personal use. The Galder court
found that the approval requirements for new drugs applied to private
99 The APA provides that a court will overturn Agency action when it is "in excess of
statutory jurisdiction, authority, or limitations, or short of statutory right." 5 U.S.C. § 706(C)
(1998).
100 Chevron U.S.A., Inc. v. NRDC, 467 U.S. 837, 842 (1984).
101 The statute reads that the FDA shall prohibit importation of drugs that it finds are
"adulterated, misbranded, or in violation of section 505.. ." 21 U.S.C. § 381(a)(3) (1998)(em-
phasis added). Section 505 is the statutory provision requiring the FDA approval of new drug
products, and states that "[n]o person shall introduce or deliver for introduction into interstate
commerce.. ." an unapproved drug. 21 U.S.C. § 355(a) (1998). The FDCA defines interstate
commerce as "commerce between any State or Territory and any place outside thereof. .. " 21
U.S.C. § 321(b) (1998).
102 See 21 U.S.C. §§ 381(a)(3), 355(a) (1998).
103 Although the line of Supreme Court cases interpreting Congressional power under the
Commerce Clause of the Constitution would be relevant to an analysis of the phrase "introduc-
tion into interstate commerce" in the FDCA, it would not be dispositive.
104 See RU-486 Hearing, supra note 25, at 175-77.
105 425 F.Supp. 244 (D.Minn. 1977).
HIDING BEHIND AGENCY DIscRETIoN
persons and that personal transportation of Laetrile from Mexico consti-
tuted an introduction into interstate commerce under the FDCA. 10 6 The
court did not consider whether the FDA should permit importation under
its personal use policy, and in fact appeared unaware that such a policy
existed. The FDA has asserted in other forums however, that the per-
sonal use exemption policy has been in effect since the 1950's.107
If the court, despite precedent, found the FDCA was ambiguous
with regard to whether personal use constituted introduction into inter-
state commerce, its next decision would be whether the Agency's inter-
pretation of ambiguous statutory authority was a permissible construction
of the FDCA. 10 8 Given that FDA's interpretation of § 801 as prohibiting
the importation of all unapproved drug products is long standing and
well established, a court would almost certainly defer to the Agency's
interpretations.109 Moreover, Congress recently amended the FDCA to
explicitly state that a connection with interstate commerce is to be pre-
sumed sufficient to give the FDA the authority to enforce the FDCA's
drug requirements." 0 Because the FDA is well-qualified and charged
with the determination of drug safety and efficacy, it is unlikely a court
would second guess an Agency determination that all unapproved drugs
should be prohibited from importation."'
D. FDA's APPLICATION THE LAW TO THE FACTS IN QUESTION
1. Enforcement Decision Committed to Agency Discretion
Having determined that the FDA acts within the bounds of the
FDCA and the Constitution in denying importation for personal use gen-
erally, you could next argue that the court should review the Agency's
106 See id. at 248.
107 Although its substance is unknown, some form of the personal use importation was
put in writing as early as 1954 as a directive to the Agency's district offices from FDA's
Division of Field Operations. See RU-486 Hearing, supra note 25, at 175-77.
108 See Chevron U.S.A., Inc. v. NRDSC, 467 U.S. 837, 843 (1984).
109 See, e.g., General Electric Co. v. Gilbert, 429 U.S. 125 (1976); NLRB v. Bell Aero-
space Co., 416 U.S. 267 (1974)(because the agency's decision departed from a long-standing
interpretation of its statute, the decision merited little judicial deference).
110 See 21 U.S.C. §379a (1998). Even if a court ruled that the FDA did not have the
authority to prohibit the importation of unapproved drug products for personal use as a viola-
tion of § 505 of the FDCA, the FDA could simply then reassert its authority on other grounds
and reissue such a ruling. The Agency could argue, for example, that because it has no assur-
ance that unapproved drugs are manufactured in accordance with its Good Manufacturing
Practices, such products must be presumed to be adulterated. See 21 U.S.C. § 351(a)(2)(b)
(1998). Alternatively, because the FDA has not reviewed the indications of directions for use,
the Agency could argue that unapproved drug products should be assumed to be misbranded.
111 See, e.g., Lyng v. Payne, 476 U.S. 926, 939 (1986)(court will defer to the Agency's
interpretation of its directive); United States v. Bacto-Unidisk, 394 U.S. 784 (1969)(because its
overriding purpose is to protect public health, the FDCA must be given a liberal construction
in accordance with that purpose).
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application of its policy to the particular situation at hand. At this point,
a court might refuse to review FDA's implementation of its personal use
exemption policy at all, arguing that it was an enforcement decision that
was judicially unreviewable.
Under § 701(a)(2) of the APA, courts are prohibited from reviewing
agency action that "is committed to agency discretion by law." 112 The
controlling case is Heckler v. Chaney,113 in which the FDA refused to
initiate an enforcement action against a state for the use of an injectable
drug for capital punishment although the drug was not approved for that
use. The Supreme Court held that FDA's decision of whether to initiate
an enforcement action was exempt from judicial review as a matter com-
mitted to agency discretion under § 701(a)(2).114
Since the inception of the personal use importation exemption pol-
icy, the Agency has characterized the policy as an exercise of its discre-
tion not to enforce the general prohibition against the importation of
unapproved new drugs. Moreover, the FDA argues that import alerts are
simply affirmations of the statutory mandate to prohibit importation of
unapproved or otherwise violative drug products. 115 Although the abuse
of discretion doctrine is theoretically difficult, and perhaps generally un-
workable, 116 it still strongly supports the proposition that, absent a statu-
tory directive, an Agency's exercise of enforcement discretion is
generally unreviewable by the courts.
2. Review of Denial Under Arbitrary and Capricious Standard
The APA also permits courts to set aside agency action if it is arbi-
trary or capricious. 117 Even if a court were to review the application of
the personal use importation policy or the issuance of an import alert to
112 5 U.S.C. §701(a)(2) (1998). This provision of the APA would seem to be either coex-
tensive and redundant or in direct conflict with the APA's grant of judicial authority to set
aside agency action that is "an abuse of discretion, or otherwise not in accordance with
law. . ." 5 U.S.C. § 706(2)(A)(1998).
113 470 U.S. 821, 830-32 (1984). The Supreme Court found that FDA's decision not to
enforce certain provisions of the FDCA was not subject to judicial review under § 701(a)(2) of
the APA because "if no judicially manageable standards are available for judging how and
when an agency should exercise its discretion, then it is impossible to evaluate agency action
for 'abuse of discretion." Id. at 830-32 (referring to 5 U.S.C. § 701(a)(2)(1998)). The Court
explained that when an agency decides which violators it will pursue, it considers factors such
as its chances of prevailing in the action, its overall regulatory priorities, and competing uses
for agency resources, all factors which a court may have particular difficulty and little exper-
tise in reviewing. Id.
114 See id.
115 See Memorandum for the Respondents in Opposition, Benten v. Kessler, 505 U.S.
1084 (1992) (No. A-40).
116 See, e.g., Ronald M. Levin, Understanding Unrevieivability in Administrative Law, 74
MmN. L. REv. 689 (1990).
117 Court are directed to set aside agency action that is "an abuse of discretion, or other-
wise not in accordance with law .. " 5 U.S.C. § 706(2)(A) (1998).
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determine whether the FDA implemented them arbitrarily or capri-
ciously, it is unlikely that the court would overrule a FDA decision (un-
less the court determined the policy is a substantive rule as discussed
below). For example, in a recent declaratory judgement action where the
court did review FDA's implementation of the personal use importation
policy, the court stated that "[e]ven if an individual complies with
[FDA's policy] . .. ,the decision whether to permit an individual to
import the drugs remains within the discretion of the FDA."118 Given
the discretionary nature of the personal use policy's implementation, no
denial would be arbitrary or capricious unless FDA's procedure for de-
termining the approval status of a drug was itself challenged.
E. ANALYSIS OF PERSONAL USE POLICY AS A SuBSTANTIvE RULE
UNDER THE APA
Alternatively, a court could ask whether the FDA had the authority
under the guidelines of the personal use exemption policy to prohibit the
importation. In order to frame the legal inquiry in terms of whether the
Agency implemented its policy correctly, the court would have to find
that the Agency was in fact legally bound by the terms of the policy.
Such a finding, however, would be tantamount to classifying the personal
use exemption policy as a substantive rule under the APA.119 Again,
judicial precedent in this case, in particular the precedent established
under the attempt to import RU-486, is contrary to a finding that the
personal use importation policy or import alerts are substantive rules.
The APA requires that substantive (also known as legislative or formal)
rules be formulated through notice-and-comment rulemaking. 120 In gen-
eral, substantive rules are like laws in that they serve to determine the
rights of a class of people. Unlike informal policy or interpretive rules,
substantive rules are binding both on the Agency and the private persons
regulated by the rules. In determining whether an agency as complied
with the APA's procedural mandates and whether an agency rule is bind-
ing, a court must first characterize whether the policy at issue is a sub-
stantive rule.
118 Sifre v. Robles, 917 F. Supp. 137 (D.P.R. 1996). The court also affirmed the Ruther-
ford Laetrile cases as establishing that an individual has no legal right to a particular medical
treatment. See Rutherford v. United States, 616 F.2d 455, 457 (10 ' Cir. 1980), cert. denied,
449 U.S. 937 (1980).
119 The APA defines rules as "the whole or part of an agency statement of general or
particular applicability and future effect designed to implement, interpret, or prescribe law or
practice." 5 U.S.C. § 551(4) (1998).
120 The APA does not define substantive rule, but simply exempts from notice-and com-
ment rule making procedures "interpretive rules, general statements of policy, [and] rules of
agency organization, procedure, and practice." 5 U.S.C. § 553(b)(A) (1998).
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In Bellarno Intern. Ltd. v. FDA, the court overturned an FDA im-
port alert largely banning the reimportation into the United States of a
drugs originally manufactured in the United States because it was a sub-
stantive rule and thus should have been promulgated in accordance with
APA notice-and-comment rulemaking procedures. 121 The Bellarno court
identified four relevant factors in determining that the import alert was a
substantive rule: "[t]he binding effect of the pronouncement; the degree
of discretion accorded the agency in applying the pronouncement; defer-
ence to the agency's characterization; and the language of the pronounce-
ment itself."' 22 Logically, the issuance of an import alert, which
removes the discretion to permit importation of certain types of drug
products regardless of whether the drugs otherwise comply with the
FDCA, has the force and effect of a substantive rule. 123
If a court decided that the personal use exemption policy itself was a
substantive rule, it could then review FDA's implementation of the pol-
icy to determine whether the Agency's denial was arbitrary and capri-
cious and hold the policy void because it was not implemented by the
requisite notice-and-comment rule making procedures. 24 Although
compelling, this line of attack is most likely precluded by the Supreme
Court's review of FDA's refusal to permit the importation of Mifepris-
tone (RU-486) under the personal use importation policy in accordance
with an import alert as described below.
Shortly after FDA issued its 1989 Pilot Guidance for personal use
importation, the Agency came under intense Congressional pressure to
ensure its policy did not provide American women with access to the
abortifacient drug Mifepristone, better known as RU-486.'2 Unencum-
bered by procedural requirements or publicity, the FDA moved quickly
and in just three weeks issued an import alert banning the importation of
RU-486 for personal use on the grounds that the drug was unsafe. 126
Allegations at the time suggested that in addition to prohibiting the use of
121 See 678 F.Supp. 410 (E.D.N.Y 1998).
122 Id. at 413.
123 Section 801(d)(1), a part of the Prescription Drug Marketing Act of 1987, banned the
reimportation of exported products except when reimportation was by the original manufac-
turer of the drug. See Prescription Drug Marketing Act of 1987,21 U.S.C. § 381(d)(1) (1998).
124 The APA exempts form notice-and-comment procedures "interpretive rules, general
statements of policy, [and] rules of agency organization, procedure or practice." 5 U.S.C.
§ 553 (b)(A), (d)(2)(1998). Substantive or legislative rules, however, must be developed
through APA's notice-and-comment procedures or they are invalid. See, e.g., Bellarno Intern
Ltd., v. FDA, 678 F. Supp. 410 (E.D.N.Y 1988).
125 On May 5, 1989, then FDA Commissioner Frank Young received a letter from eleven
anti-abortion activist members of Congress, asking that an import alert be issued for RU-486.
Nineteen days later, FDA recommended that RU-486 be placed on the import alert list; the
alert was issued on June 6, 1989. See S. 2268, 102d Cong. (1992).
126 See FDA Import Alert no. 66-47, (Apr. 17, 1990) (visited Feb. 20, 2000) <http:ll
www.fda.gov/oralfiars/ora-import-ia6647.html>.
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RU-486 as an abortifacient, FDA's import alert also stopped promising
research on the drug's use in treating breast and other cancers. 127
In 1992, a woman named Leona Benten challenged the Agency's
right to enforce the import ban in court and sought the immediate use of
the RU-486 she had imported to terminate her pregnancy. In order to
challenge FDA's import ban, the Abortion Rights Mobilization group
flew Ms. Benten to London to obtain RU-486, where she notified the
FDA of her intention to return to the United States with the drug for use
under the supervision of her physician. She was met at the airport by
FDA personnel who seized the drug, and she and the Center for Repro-
ductive Law and Policy filed a complaint in Federal Court in New York
for return of the drug and a ruling that FDA's import ban on RU-486 was
illegal.128 In its initial decision to permit Ms. Benten to use the imported
drug, the United States District Court for the Eastern District of New
York blasted the lack of notice-and-comment rule making surrounding
FDA's issuance of the RU-486 import alert and accused the Agency of
banning RU-486 for "political considerations having no place in FDA
decisions on health and safety."'129 In the court's opinion, both the im-
port alert and the personal use exemption policy should have been imple-
mented through notice-and-comment rule making procedures. 130
On appeal to the Supreme Court, the Eastern District's order re-
turning the RU-486 to Ms. Benten was overturned, and the Agency's
right to prohibit the importation of RU-486 was confirmed on July 17,
1992.131 The Supreme Court held that Ms. Benten did not have a sub-
stantial likelihood of succeeding in her argument that the FDA was re-
quired to implement its import alert through notice-and-comment rule
making procedures. 132 The Court simply stated this conclusion without.
discussion, perhaps because the Court was forced to decide the case
within a matter of days, as RU-486 can only be safely used as an aborti-
facient during early pregnancy. 133 Despite its lack of explanation, the
Supreme Court's decision makes it unlikely that a lower court would
again find an FDA import alert to be a substantive rule.
127 See RU486 Hearing, supra note 25.
128 See Supreme Court Upholds FDA Ban on RU-486 Importation; Ban is "Undue Bur-
den" Argues Dissenting Justice, THE BLUE SHEET (FDA/Drug Research Reports), July 22,
1992, available in LEXIS, Market and Industry Library, Medical and Healthcare Folder, Blue
Sheet-Health Policy and Research File
129 Benten v. Kessler, 799 F. Supp. 281, 285 (E.D.N.Y. 1992).
130 See id. at 289.
131 See Benten v. Kessler, 505 U.S. 1084 (1992).
132 See id. at 1085.
133 See id.
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Upon taking office, President Clinton ordered a review of the
Agency's import ban on RU-486.134 Although the import ban was not
lifted, the United States non-profit group Population Council obtained
patent rights to the drugs and filed a new drug application for RU-486 in
1996. The FDA subsequently issued an "approvable letter" to the Popu-
lation Council for Mifepristone, when used in combination with mis-
oprostol, for termination of early pregnancy. 135 After the 1996 tentative
approval, the Population Council ran into difficulties finding a manufac-
turer willing bringing the drug to market. In early 1999 however, the
Population Council announced it had located a manufacturer for the drug
and it was hoped that FDA would give final approval by the end of the
year. 136 On February 18, 2000, the FDA issued another "approvable let-
ter" for Mifepristone when used in combination with misoprostol.
Although implying that the early issues blocking final approval of RU-
486 had been resolved, the Agency did not comment as to the nature or
extent of the remaining issues barring final approval. 137
However, a court would be even less likely to find that the personal
use exemption policy is a substantive rule that should have been imple-
mented through notice-and-comment rule making procedures. Because
the FDA has consistently characterized the personal use exemption as a
discretionary policy made by individual FDA employees, it cannot easily
be characterized as "binding." Unless the Agency ostensibly required its
personnel to follow the policy, a court would also be likely to find the
personal use exemption to be an interpretive rule exempt from APA-
mandated rule making procedures. 138
134 See Mifepristone (RU-486) Proposed Distribution System is Acceptable, But Abortion
Training Process Raises "Serious Concerns," Advisoy Committee Concludes, THE PINK
SHEET (FDA/F-D-C Reports), July 29, 1996, at 13-14, available in LEXIS, Market and In-
dustry Library, Medical and Healthcare Folder, Pink Sheet-Pharmaceuticals, Prescriptions and
OTC Medications File.
135 FDA Advisory Committee Reviews Mifepristone, July 19, 1996. (last visited March 4,
2000) <http:lwww.fda.govbbs/topics/ANSWERSIANS0O748.html>. The FDA issues "ap-
provable letters" when relatively minor issues necessary for final approval remain unresolved.
136 See Marc Kaufman, Abortion Pill Inches Closer to Production: American Markerter
Hopeful that Drug Will Be Available by the End of the Year, WASH. POST, Mar. 23, 1999, at
Z07. In addition, the press reported that fifteen sites nation-wide were participating in a
clinical trial of RU-486 sponsored by the Abortion Rights Mobilization (ARM), an advocacy
group. See idt.
137 See FDA Issues Approvable Letterfor Mifepristone, Feb. 18, 2000. (last visited March
4, 2000) <http:llwww.fda.gov/bbs/topics/ANSWERS/ANS01005.html>.
138 For example, the United States Court of Appeals for the Fifth Circuit recently held
that a FDA Compliance Policy Guide setting forth guidelines on the permissible scope of
pharmacy compounding activities was interpretive rule exempt from APA rulemaking proce-
dures. See Professionals and Patients for Customized Care v. Shalala, 56 F.3d 592 (5th Cir.
1995).
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VI. IMPLEMENTING THE PERSONAL USE EXEMPTION
THROUGH SUBSTANTIVE REGULATIONS
FDA's personal use exemption policy is probably best characterized
as an interpretive rule that does not require notice-and-comment rule
making. The FDA, however, could give binding effect to the personal
use importation policy by explicitly promulgating it as a substantive rule
through notice-and-comment rule making procedures. 139 Once the FDA
implements a substantive regulation, the Agency and those it regulates
are bound by the terms of the rule.140 That is, the FDA would give up its
discretion to deny importation for personal use if an individual met spe-
cific criteria established by the rule, while individuals would be on notice
that they must meet the rule's criteria in order to import unapproved
drugs for personnel use. At the administrative hearing of a denial, the
question would be whether the particular individual met the criteria
under the personal use exemption rule. Judicial review, assuming the
court agreed the rule was substantive, would focus on the same question.
If the legislative effect of the policy were challenged in court, the
FDA could assert that the FDCA's ban on the import of unapproved drug
products for introduction into interstate commerce can be interpreted to
permit importation for personal use - the very opposite of the argument
FDA has traditionally asserted. Because the FDA would be departing
from long-standing precedent, the authority of the policy to bind the
Agency and those it governs might be vulnerable in a judicial review. 14 1
The FDA is also free to implement interpretive rules or general pol-
icy through notice-and-comment rule making if it so chooses. Congress
itself recently charged the FDA with abiding by its guidance documents
and ensuring public participation in the formation and implementation of
those that are important policy changes, obviously recognizing that much
of FDA's guidance can have a substantial impact on substantive
rights.142 At the very least, the FDA could implement its personal use
139 A substantive rule must be "rooted in a grant of [quasi-legislative] power by the Con-
gress." Chrysler Corp. v. Brown 441 U.S. 281, 301 (1979). Congress has given the FDA the
authority to "prescribe regulations of the efficient enforcement of section 381 [governing im-
ports] of this title." 21 U.S.C. § 371(b) (1988).
140 See United States v. Nixon, 418 U.S. 683, 694-95 (1974).
141 See, e.g., General Electric Co..v. Gilbert, 429 U.S. 125 (1976); NLRB v. Bell Aero-
space Co., 416 U.S. 267 (1974)(because the agency's decision departed from a long-standing
interpretation'of its statute, the decision merited little judicial deference).
142 Congress was explicit when it stated:
Although guidance employees of the Food and Drug Administration do not deviate
from such guidance without appropriate justification and supervisory concur-
rence ... For guidance documents that set forth... policy that are of more than a
minor nature, complex scientific issues, or highly controversial documents shall not
be binding on the Secretary, the Secretary shall ensure that issues, the Secretary shall
ensure public participation prior to implementation of guidance documents, unless
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importation policy as a guidance document, including import alerts,
through notice-and-comment rule making procedures.
VII. CONCLUSION
There are many good reasons for the FDA to implement the per-
sonal use exemption, including import alerts, through the APA's notice-
and-comment rule making procedures. First, the Agency has not abided
by or acted consistently within the bounds of its personal use exemption
as it is found in its personnel manual. In the case of the AIDS buyers'
clubs, the Agency paid lip-service to the policy, but permitted signifi-
cantly more unapproved drugs to be imported than the written policy
would justify. On the other hand, the FDA appears to have responded to
political pressure rather than a public health mandate when it issued its
import alert on RU-486. Finally, in all of the controversy over Laetrile,
many of those seeking to use Laetrile were not even aware of FDA's
personal use importation policy.
Regardless of whether the effect of the Agency's respective deci-
sions was good or bad, FDA's implementation of the personal use ex-
emption certainly does not provide the type of interest-group
participation, consistency, fairness and accountability desired in agency
action. In contrast, notice-and-comment rule making would bring inter-
ested parties into the discussion to develop a personal use importation
policy that was flexible and permitted independent review while safe-
guarding the public health.
Poised as it is at the end of its experience with the widespread im-
portation of unapproved AIDS therapies, the Agency is in an ideal posi-
tion to turn the wisdom gained by its experience into a regulation that
will safeguard both the quality of and access to unapproved drug prod-
ucts. Moreover, if, as is hoped, the need for access to unapproved
AIDS-related therapies continue to diminish, the existence and use
of the personal use exemption will become increasingly rare. A formal
regulation would at least give those searching for access to an unap-
proved drug notice that the FDA will allow such access under certain
circumstances. A list of the circumstances under which the FDA would
permit personal use importation would also provide a court with mean-
ingful standards in a review of FDA's application of the law.
As political and societal values change over time, there is no guar-
antee that the Agency's current benevolent attitude toward personal use
importation will continue, or that the next group seeking access to unap-
the Secretary determines that such prior public participation is not feasible or
appropriate.
Food and Drug Administration Modernization Act of 1997, § 506, 21 U.S.C. § 356 (1998).
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proved drugs through the exemption will be successful - other groups
may not have the political or social clout to ensure FDA's personal use
importation policy is implemented (or expanded) for their benefit. At
least one person with personal experience of the importation of AIDS-
related therapies under the personal use exemption agrees that the poten-
tial for abuse of the policy as applied to individuals, or other, less organ-
ized groups, necessitates a formal personal use exemption policy.' 43
Another AIDS-activist believes that their movement has changed FDA's
stance toward people with life-threatening diseases forever, ensuring ac-
cess to unapproved products. He fears that implementing a formal policy
may lead to a more narrow and restrictive policy. 44 Given the uneven
history of the policy's implementation, it is a risk worth taking.
A regulation governing importation for personal use could also set
forth guidelines for the issuance of import alerts. Because of the nature
of import alerts, the FDA is justifiably reluctant to give up its ability to
issue such alerts without procedural impediments. The Agency could
reserve the right unilaterally to issue import alerts under its regulation,
however, and simply create an administrative procedure requiring the
Agency to justify the alert with stated health and safety reasons, publish
both the alert and the justification within a designated time-frame, and
provide for public comment. Such a regulation would ensure that FDA
would at least be forced to detail its rational for banning certain drugs
and to publish the comments of those challenging the propriety of the
Agency's ban.
There will always be companies willing to export unapproved drug
products to the United States for commercial gain regardless of the legal-
ity of their actions. FDA's challenge is to keep abreast of the increasing
glut of commercial information available to American consumers, espe-
cially over the Internet, in order to protect them from unsafe products.
The implementation of a rule governing the personal use exemption pol-
icy could serve to put these companies on notice that the FDA will not
allow importation under the policy for commercial purposes.
Individual autonomy and self-determination are traditional Ameri-
can values. Nowhere are these rights more fundamental than in an indi-
vidual's right to control his or her own body. Unless their actions will
harm others, it is unconscionable to risk denying people without a future
that hope which they can find.
143 Personal Communication with Ron Mealy, Carl Vogel Center (Feb. 8, 1999).
144 Personal Communication with Mark Niedzolkowsk, Editor, The PWA Heath Group
Newsletter (Feb. 2, 1999).
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